Processa Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Processa Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $152.94K, a 97.58% decline year-over-year.
- Processa Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $200.00K, a 95.49% decline year-over-year.
- Processa Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $2.86M, a 207.09% increase year-over-year.
- Processa Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $6.32M.
- Processa Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2025 was $16.60M, a 113.80% increase from fiscal 2024.
- Processa Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2024 was $7.76M, a 22.21% increase from fiscal 2023.
- Processa Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2023 was $6.35M.
- Processa Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2021 was $9.88M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $152.94K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $200.00K 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $16.60M 10-K · filed 2026-03-18 | |
| 2025-09-30 | $2.86M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $6.32M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $4.44M 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $7.76M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $931.29K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $6.28M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $6.35M 10-K · filed 2025-03-20 | |
| 2023-03-31 | $6.35M 10-Q · filed 2024-10-30 | |
| 2021-12-31 | $9.88M 10-K · filed 2023-03-30 | |
| 2021-06-30 | -$9.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | $9.88M 10-Q · filed 2022-11-08 | |
| 2018-12-31 | -$90.41K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $2.87M 10-K · filed 2020-03-06 |
| 2018-09-30 | $1.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | |
| 2018-06-30 | $2.97M 10-Q · filed 2019-11-14 | |
| 2016-12-31 | $4.27M 10-K · filed 2018-04-16 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $88.00K 10-K · filed 2017-09-25 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-01 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | |
| 2015-03-31 | $88.00K 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $366.32K 10-K · filed 2015-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |